AbbVie Inc.
ABBVLast close · Oct 16, 2026285.42+2.02 (+0.71%)
Market cap$504.4B
10 firms' latest targets, last 90 days: median $300.00 ($288.00–$320.00), 5% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-08 | Cantor Fitzgerald | $290.00 | ▲ 9% | +2% |
| 2026-10-07 | Morgan Stanley | $310.00 | ▲ 5% | +9% |
| 2026-10-06 | Scotiabank | $320.00 | — | +12% |
| 2026-09-10 | HSBC | $315.00 | ▲ 5% | +10% |
| 2026-08-20 | Piper Sandler | $303.00 | ▲ 2% | +6% |
| 2026-08-17 | Wells Fargo | $300.00 | ▲ 2% | +5% |
| 2026-08-13 | Wolfe Research | $300.00 | — | +5% |
| 2026-08-04 | Guggenheim | $288.00 | ▲ 10% | +1% |
| 2026-08-03 | Canaccord Genuity | $290.00 | ▲ 3% | +2% |
| 2026-07-29 | Barclays | $300.00 | ▲ 9% | +5% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $54.3B | -6% | $2.72 | -59% | est. $54.0B+0% | est. $11.13 | 16 |
| 2024reported | $56.3B | +4% | $2.39 | -12% | est. $56.0B+1% | est. $10.08 | 17 |
| 2025reported | $61.2B | +9% | $2.36 | -1% | est. $61.0B+0% | est. $9.94 | 18 |
| 2026 | $67.6B | +11% | $13.92 | +40% | $67.5B–$68.0B | $13.75–$14.19 | 18 |
| 2027 | $73.5B | +9% | $16.38 | +18% | $71.9B–$74.9B | $15.52–$17.37 | 16 |
| 2028 | $79.0B | +8% | $17.88 | +9% | $75.2B–$81.7B | $15.39–$20.78 | 20 |
| 2029 | $83.5B | +6% | $19.82 | +11% | $81.5B–$84.8B | $19.20–$20.23 | 10 |
| 2030 | $85.3B | +2% | $20.97 | +6% | $83.3B–$86.6B | $20.32–$21.40 | 10 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.